anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1,140,443. Therapeutic compositions. S. L. SANTORELLI. 27 May, 1966, No. 23987/66. Heading A5B. Therapeutic compositions for topical application having bactericidal and fungicidal effects on skin disorders comprise propylene glycol containing, per 100 cc of glycol, at least 10 grams of salicylic acid and a total of at least 0.1 gram of one or more of the antiseptics sodium dibromoxymercurifluorescein, sodium ethylmercurithio salicylate, iodine/ sodium iodide mixtures and polyvinylpyrrolidone-iodine complex. The glycol is preferably saturated with salicyclic acid and this saturated solution may comprise per 100 cc glycol, 0.1 gram of sodium ethylmercurithiosalicylate, 0.1 gram of ethanolamine, 0.03 gram ethylenediamine, and lcc acetone. The composition may be applied as a spray.
The SARS-CoV-2 pandemic has left millions of individuals with a host of post-viral symptoms that can be debilitating and persist indefinitely. To date there are no definitive tests or treatments for the collection of symptoms known as "Long COVID" or Post-acute sequelae of COVID-19 (PASC). Following our initial case report detailing improvement of Long COVID symptoms after sequential bilateral stellate ganglion blockade (SGB), we performed a retrospective chart analysis study on individuals treated with the same protocol over the course of six months (2021-2022) in our clinic. Patients self-reported symptoms on a 10-point scale as part of optional patient follow-up using an online survey. After one month or more following treatment, patients reported striking reductions in Fatigue, Worsening of Symptoms following Mental and Physical Activity, Memory Problems, Problems Concentrating, Sleep Problems, Anxiety, and Depression. Loss of Taste and Loss of Smell in some individuals did not respond to treatment, likely indicating structural damage following infection. This study suggests that neuromodulation may provide relief of Long COVID symptoms for at least a subset of individuals, and provides support for prospective studies of this potential treatment.
Brigatinib 90 mg, tablets, orally, once daily for 7 days, followed by Brigatinib 180 mg, tablets, orally, once daily for until objective disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, as assessed by the investigator, or intolerable toxicity. Participants who experienced progression on the 180 mg dose and had not experienced toxicities greater than Grade 2 had the option to receive brigatinib 240 mg QD based on investigator's discretion, up to 20 months until data cut-off: 30 September 2020. Participants who experienced progression on any doses but judged as still benefiting from the study treatment by the investigator may continue to use the current dose, up to study end.
Fathers allocated to the Usual Care arm will receive the clinical care typically provided to parents experiencing mental health difficulties by an Early Parenting Centre or community health service. Within 2 weeks of baseline assessment, Usual Care participants will receive a brief psychological consultation from Tweddle's Clinical Manager.
The present invention provides an apparatus and method for viewing medical images on a handheld computer. After medical images are obtained, they could be either be transferred directly to a handheld computer or indirectly via a computer. The medical images could also be transferred from one handheld computer to another handheld computer. A conversion of medical images is performed to convert the image from a standard format to an appropriate format for the selected handheld computer. One or more interactive tools are provided for displaying the one or more converted medical images on the handheld computer. An exemplary embodiment is provided that shows the conversion of a DICOM format medical image so that it could be displayed and viewed on a personal digital assistant. The advantage of the present invention is that it allows one to obtain, view and analyze medical images completely wireless and mobile on a personalized handheld computer.
Objective: Preterm neonates encounter hyperoxia relatively early, and are more exposed to hyperoxic stress due to their insufficient antioxidant defense mechanisms. This study was planned around the hypothesis that this hyperoxic effect may cause a disposition to future acute seizures. Methods: This study was composed of two main groups Hyperoxy and Control (Room air with normal O2 levels) Groups. Group 1 - hyperoxia (Study): The experimental group consisted of premature newborn rats exposed to hyperoxia with their dams from birth to postnatal day 5. Group 2 - room air (Control): The group was not exposed to hyperoxia and housed the same room air and temperature as their dams. Female, Acute Epilepsy Female, Male, Acute Epilepsy Male, and a total of eight subgroups were formed in both the control and hyperoxia groups. When the rats were two months old, intracranial electrodes were attached to obtain electrocorticography (ECoG) recordings. Pre-model recordings were taken, after which an acute pentylenetetrazole (PTZ) model of absence seizure was induced by the intraperitoneal administration of PTZ at 50 mg/kg. ECoG records were examined using the PowerLab system for 180 min. Spike wave number and duration, Spike wave frequency and amplitude data were evaluated.Results: Seven female and three male rats were exposed to hyperoxia, and a control group of five female and three male rats were included in the study. The median interquartile range for spike wave latency in the hyperoxia and control groups were 1112 (644-1545) and 654 (408-1152), frequency 4476 (3120-7421) and 3934 (2264-4704), and amplitude data 0.68 (0.59-0.79) and 0.52 (0.37-0.67), respectively. Although a difference was observed in median values capable of constituting susceptibility to epilepsy, the difference was not statistically significant (p > 0.05). In terms of gender, spike-wave counts were significantly higher in female rats (p < 0.05). Females exposed to hyperoxia were more susceptible to epilepsy than both males and females in the control group (p < 0.05).Conclusion: Exposure to hyperoxia in the first days of life of premature neonates due to their susceptibility to oxidative stress and insufficient antioxidant mechanisms, can cause a disposition to acute seizures. As a result, females exposed to hyperoxia during the neonatal period may be prone to epilepsy in maturity.
A traditional Chinese medicine formula for treating alopecia seborrheica is disclosed. The traditional Chinese medicine formula is characterized in that the traditional Chinese medicine formula comprises prepared fleeceflower root, prepared rehmannia root, cacumen platycladi, solomonseal rhizome, Chinese wolfberry, drynaria roosii, angelica sinensis, radix paeoniae alba, and Chinese date; and a preparing and taking method includes a step of weighing the abovementioned medicine materials by weight, mixing, adding the mixture into a gallipot, adding three big bowls of water, dipping for 3 h, boiling with big fire, slowly decocting with soft fire for about 30-40 min until only one bowl of medicine liquid is left, filtering to obtain the medicine liquid and keeping dregs; a step of adding two big bowls of water, boiling with big fire, slowly decocting with soft fire for about 20-30 min until only half bowl of medicine liquid is left, filtering to obtain medicine liquid and keeping dregs; and a step of repeating the second step. The medicine liquid is divided into two equal parts one of which is taken in the morning and the other of which is taken at night when the medicine liquid is warm. A person should lie flat for a rest for 30 min after taking the medicine liquid. One dosage of the traditional Chinese medicine formula is taken each day, and a treating course comprises nine dosages. The traditional Chinese medicine formula overcomes the problem that treatment at present for the alopecia seborrheica is great in side effects, and the like, and the formula is suitable for clinical treatment of the alopecia seborrheica.
BACKGROUND: Extravasation (EV), or the leakage of anticancer drugs into perivascular and subcutaneous tissues during intravenous administration, can cause serious conditions that may require surgical intervention. Therefore, updated guidelines for EV based on systematic review are needed. Additionally, classifications for anticancer drugs that cause EV are not standardized across the current guidelines, and some novel drugs have not been classified. Therefore, this study aimed to formulate guidelines using evidence-based information for shared decision making on prevention, early detection, treatment, and care for EV in Japan and provide additional classification for tissue injury based on systematic review.
MATERIALS AND METHODS: The members of the Japanese Society of Cancer Nursing (JSCN), Japanese Society of Medical Oncology (JSMO), and Japanese Society of Pharmaceutical Oncology (JASPO) were surveyed about significant clinical challenges related to EV, and 17 clinical questions (CQs) were formulated. PubMed and ICHUSHI Web were searched using the Patient, Intervention, Comparison, and Outcomes terms listed in each CQ as key words. For the classification of new drugs, articles published through February 2021 were selected using the search terms 'extravasation', 'injection-site reaction', 'adverse events', and the names of individual drugs as key words.
RESULTS: Recommendations based on the results of randomized controlled trials (RCTs) were made with regard to the selection of central venous (CV) devices (CQ2, CQ3a, CQ3b, and CQ3c), regular replacement of peripheral venous catheters (CQ5), and use of fosaprepitant (CQ7). These CQs are novel and were not mentioned in previous guidelines. Warm compression monotherapy (CQ10b) and local injection of steroids (CQ12) are discouraged for the management of EV. Ten new drugs were classified for EV tissue injury.
CONCLUSIONS: This study provides updated guidelines for the prevention and treatment of EV, which can be used to help health care providers and patients and their families practice better EV management.
Cortical spreading depression (CSD) is a wave of mass neuronal firing and neuronal and glial depolarisation which propagates through grey matter in the central nervous system in response to a pathologic stimulus, at a rate of between 1 and 5 mm per minute. First described by Leão in 1944 as a sudden depression of ECoG amplitude spreading across the cortex of the rabbit (Leao, A. A. P. 1944), CSD can be elicited in experimental animals by chemical, electrical, and mechanical stimuli, with varying degrees of ease. CSD provoked in healthy, normally perfused neural tissue does not induce persistent metabolic stress or cellular damage, and indeed such induction of CSD in animal experiments may confer protection against the adverse effects of a subsequent ischaemic insult (Kobayashi, S. et al. 1995).

In animal models of focal cerebral ischaemia, usually induced by occlusion of the middle cerebral artery, a spontaneous phenomenon occurs around the periphery of the core territory, with electrophysiological features essentially identical with CSD, and similar capacity to propagate across cerebral cortex. Designated "peri-infarct depolarisation" (PID), this event is associated with infarct expansion, or recruitment of at-risk cortical territory into the expanding core, and has been shown capable of causing this expansion, in the absence of therapeutic intervention. Indeed it has been hypothesized that glutamate release may be involved in PID generation, and that excitotoxicity may accomplish detrimental effects via this route (Hossmann, K. A. 1994), (Obrenovitch, T. P. and Urenjak, J. 1997). Some experimental neuroprotection treatments for stroke act to decrease the incidence of PID (Iijima, T. et al. 1992;Chen, Q. et al. 1993;Busch, E. et al. 1996).

In traumatic and ischaemic (especially in middle cerebral artery occlusion and aneurysmal subarachnoid haemorrhage) brain injury in humans, a phase of delayed deterioration often associated with severe and refractory brain swelling develops between 2 and 5 days after the initial ictus, and is associated with poor or fatal outcome. The cause and mechanism of this deterioration remain poorly understood, and the possibility exists that CSD/PID events might contribute to deterioration.

To date, CSD or PID have been reported in only ten human subjects in two papers (Mayevsky, A. et al. 1996; Strong, A. J. et al. 2002). Strong et al. reported that transient ECoG suppressions suggestive of depolarisations are common - but by no means universal - after brain injury in humans. Sub-dural ECoG electrode strips were placed in 14 patients who had undergone craniotomy for trauma or intracranial hemorrhage; monitoring was for up to 60 h following the injury. Five of these patients (36%) showed patterns of ECoG depression consistent with PID/CSD in brain regions adjacent to the primary injury.
Subjects were randomized to receive Doxycycline capsules. The capsules were taken once daily for 6 weeks and evaluated every 2 weeks.
The treatment scheme is purely welfare and therefore it does not require any approval of ethical committees for his application. It gathers the basic ideas of the present treatment of the AML, with optional induction according to preference of each center with daunorubicin or Idarubicin (x3) associated to AraC (x7). The patients who reach CR consolidate with an identical cycle to the used one in the induction. Later (if pte has identical donor HLA, and as much it as their doctors has preference by this option) receive allogenic transplant. The other patients who reach CR receive two intensifications, one that AraC to intermediate dose contains and another one with autologous transplant, previous preparation with Busulfán, Etoposide and AraC. Later all antileucemic treatment is suspended until possible relapse. This scheme of treatment is accompanied by a valuation of the quality of the CR with traditional morphology, Immunocytometry and molecular genetic study and of a pursuit of residual minimum disease (EMR) using the same techniques.
The group will undergo laparoscopic implantation surgery. The device will be activated two weeks post-implantation and the subject will receive EndoStim stimulation for first six months of study and continue with EndoStim stimulation from Month 6 thru end of study.
Miscarriage poses a significant threat to both maternal and fetal health. Its etiology remains unknown, and there are no established effective identification or prevention strategies. A low-oxygen environment in early pregnancy is a physiological necessity for embryonic and placental growth. Hypoxia-inducible factors are a family of classic hypoxia signaling molecules whose expression level may fluctuate abnormally because of an imbalance in oxygen levels. Its unusual fluctuations initiate multiple signaling pathways at the maternal womb. Hypoxia-inducible factors are a family of classic hypoxia-signaling molecules and immune tolerance. Notably, aberrant regulation of these processes may lead to miscarriage. This review aims to clarify how the hypoxia-inducible factor-1α mediates the aberrant regulation of biological processes, including autophagy, metabolic reprogramming, et al., and how these effects impact trophoblasts and other cells at the maternal-fetal interface. These findings provide new insights into potential therapeutic and preventive strategies for miscarriage.
PURPOSE:To obtain a pessary comprising a hard fat (a mixture of monoglyceride, diglyceride and triglyceride of 8-18C straight-chain saturated fatty acid) having a salt of dehydroepiandrosteronsulfate and a specific hydroxyl group valency, having excellent strage stability and capable of promoting extensibility and heat activation of neck of the womb and improving condition for preparing delivery. CONSTITUTION:A hard fat (a mixture of monoglyceride, diglyceride and triglyceride of 8-18C straight-chain saturated fatty acid) having <=50 hydroxyl group valency is heat-melted and a salt of dehydroepiandrosterone sulfate (DHAS) is uniformly mixed with the hard fat and the mixture is cast into a mold separately in a definite amount and cooled to provide the aimed product. The salt of DHAS is a metal salt such as Na salt, k salt, Li salt, Mg salt or ammonium salt and preferably used as a crystalline powder having 3-20mum average particle size. The hard fat is blended in an amount of 1-20, preferably 3-10wt% part based on wt. part of the salt of DHAS. The pessary is administrated 1-3 times per day in an amount of 100-1,500mg/dose based on the salt of DHAS.
The invention relates to a total-humanized anti-hepatitis B virus neutralizing antibody. The heavy chain variable region of the antibody has the amino acid sequences shown in the sequence tables of SEQ ID NO 2, SEQ ID NO 3 and SEQ ID NO 4. The light chain variable region of the antibody has the amino acid sequences shown in the sequence tables of SEQ ID NO 6, SEQ ID NO 7 and SEQ ID NO 8. The total-humanized anti-hepatitis B virus neutralizing antibody has the advantages that the peripheral blood of a volunteer with the high anti-hepatitis B virus immune globulin titer is collected, specific plasma cells are separated, antibody genes of single cells are fished and expressed in vitro, the functional experiment verification is carried out, and one strain of anti-hepatitis B virus antibody with the optimal neutralizing activity is obtained through screening. The antibody has the advantages of being total in human source, high in specificity, high in sensitivity and free of differential source seroreaction. Safety and high efficiency are achieved, side effects are avoided, mass preparation in vitro can be achieved, and the antibody is suitable for large-scale industrial production.
The invention discloses a novel Lck small-molecule inhibitor for inhibiting graft-versus-host disease. The novel Lck small-molecule inhibitor is used for inhibiting graft-versus-host disease (GVHD) caused by allogeneic chimeric antigen receptor T-cells (CAR-T). The novel Lck small-molecule inhibitor FL-2501 has a following molecular formula. A small-molecule compound has high-strength selective inhibitory action on TCR signals is screened from a compounds library by a high-throughput screening method; the small-molecule compound includes pharmaceutically acceptable salts and prodrugs. The small-molecule compound is the protein kinase Lck selective inhibitor, capable of inhibiting transmission of TCR signals in CAR-T cells during in vitro tests, without affecting proliferation and tumor-killing functions of the CAR-T. The small-molecule compound is effective in inhibiting GVHD caused in the treatment course of allogeneic CAR-T and promoting clinical application of the allogeneic CAR-T.
Circadian rhythms optimize nutrient homeostasis by orchestrating catabolic and anabolic metabolism to appropriate times of the 24 hour day. Chronic circadian rhythm disruption predisposes individuals to metabolic diseases including obesity and type 2 diabetes. Conversely, maintaining a daily rhythm of feeding and fasting cycles sustains a robust circadian rhythm which improves cellular bioenergetics and results in improved metabolism. Time-restricted eating (TRE) is a specific feeding-fasting pattern in which feeding is restricted to 8-12 hours a day.

At the beginning and end of the study (which will be three months in duration), the following parameters will be measured: height, weight, body mass index, percent body fat, waist/hip circumference and blood pressure. Blood sugar levels will be monitored continuously for 2 weeks at a time at the beginning and end of the study using a continuous glucose monitor. Additionally, a dual energy X-ray absorptiometry (DXA) scan will be used to collect information about body composition. Information will be collected about the mitochondria with a muscle biopsy. Participants will use a smartphone application (called myCircadianClock (mCC), developed by the Salk Institute) to keep track of food/beverage intake and will wear a wrist-worn actigraphy device to monitor physical activity levels and sleep.
BACKGROUND: The surgical removal of impacted third molars is usually carried out by an oral/maxillofacial surgeon. Two specific risks of surgical removal of impacted third molars are oroantral communication (OAC) when extracting ​​upper third molars and hypesthesia of the inferior alveolar nerve (IAN) ​​when extracting lower third molars. The aim of this study is to determine the distribution of complications in deeply impacted third molar surgery, to identify specific risk factors influencing the most common perioperative (OAC, IAN hypesthesia) and to compare these results with other studies.
MATERIALS AND METHODS: The clinical findings, digital panoramic radiographs, intra- and postoperative data of 80 patients with a total of 232 impacted third molars that had been subjected for tooth extraction, from December 2022 and August 2023, were collected and analyzed. Perioperative complications (IAN hypesthesia, OAC, hypesthesia lingual nerve, postoperative bleeding, postoperative infection) were identified. A risk analysis for OAC and IAN hypesthesia was performed regarding perioperative data.
RESULTS: Overall, the rate of OAC for the right upper third molar was 12.8% and for the left upper third molar 15.6%. The complication rates regarding transient hypesthesia were 8.1% for the left IAN and 7.3% for the right IAN. The distance to maxillary sinus, the depth score according to Pell and Gregory, the bone coverage score, the operation time, the tooth's angulation and the type of surgeon (oral surgeon, DMD) were identified as significant risk factors for the occurrence of OAC. The minimum distance to IAN, the bone coverage score, the total operation time and the operation by an oral surgeon (DMD) were identified as significant risk factors for hypesthesia of the IAN.
CONCLUSION: Next to the risk factors from above, the present study is one of the first showing that patients who were primarily operated on by an oral surgeon (DMD) and not a maxillofacial surgeon (MD, DMD) showed higher rates of OAC and IAN hypesthesia in impacted third molar extraction. The results of this study can serve as a baseline for further studies to investigate complication patterns in impacted third molar surgery.
Being normal weight according to body mass index reference system, being 10-18 years old, being volunteer for the research and able to walk and cooperate are the inclusion criteria. Having comorbidities which may affect exercise performance and other physical tests, diagnosed with the cardiovascular problems, musculoskeletal and neurological diseases, cognitive or motor limitation or other chronic diseases are exclusion criteria.
The dosage of pindolol tablets should be individualized. The recommended initial dose of pindolol tablets is 5 mg b.i.d. alone or in combination with other antihypertensive agents. An antihypertensive response usually occurs within the first week of treatment. Maximal response, however, may take as long as or occasionally longer than 2 weeks. If a satisfactory reduction in blood pressure does not occur within 3 to 4 weeks, the dose may be adjusted in increments of 10 mg/day at these intervals up to a maximum of 60 mg/day.